Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

@article{DeMatteo2009AdjuvantIM,
  title={Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.},
  author={Ronald P. DeMatteo and Karla V. Ballman and Cristina R Antonescu and Robert G Maki and Peter W. T. Pisters and George Daniel Demetri and Martin E. Blackstein and Charles David Blanke and Margaret M von Mehren and Murray F. Brennan and Shreyaskumar Patel and Martin McCarter and Jonathan A. Polikoff and Benjamin R. Tan and Kouros Owzar},
  journal={Lancet},
  year={2009},
  volume={373 9669},
  pages={1097-104}
}
BACKGROUND Gastrointestinal stromal tumour is the most common sarcoma of the intestinal tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-derived growth factor receptor alpha proteins, and is effective in first-line treatment of metastatic gastrointestinal stromal tumour. We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour… CONTINUE READING